Type 1 Diabetes Obesity Overweight
Conditions
Interventions
DRUG: Tirzepatide(Other Name: LY3298176)
Administered SC
DRUG: Placebo
Administered SC
(Study Arms)
Experimental: Tirzepatide Dose 1
Participants will receive tirzepatide subcutaneously (SC)
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Have type 1 diabetes and on insulin treatment for at least one year prior to screening - Have an HbA1c value of 7.0% to 10.5% inclusive, at screening - Have a body mass index (BMI) of >=25 kilograms per square meter (kg/m2) at screening - Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study
Exclusion criteria
Exclusion criteria: - Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization. - Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. - Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema - Have had chronic or acute pancreatitis - Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40 | — |
Countries
Argentina, Brazil, Denmark, France, Germany, Israel, Italy, Japan, Mexico, Puerto Rico, Spain, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed